Cantalejo-Díaz Miguel, Ramia José M, Álvarez-Busto Iñaki, Kokas Balint, Blanco-Fernández Gerardo, Muñoz-Forner Elena, Oláh Attila, Montalvá-Orón Eva, López-López Víctor, Rotellar Fernando, Eker Hasan, Rijken Arjen, Prieto-Calvo Mikel, Romano Fabrizio, Melgar Paola, Machairas Nikolaos, Demirli Atici Semra, Castro-Santiago Maria Jesús, Lesurtel Mickaël, Skalski Michal, Bayhan Hüseyin, Domingo-Del-Pozo Carlos, Hahn Oszkar, de Armas-Conde Noelia, Bauzá-Collado Mirella, Serradilla-Martín Mario
Department of Surgery, Hospital Reina Sofía, Tudela, Spain.
Department of Surgery, Hospital General Universitario Dr. Balmis, ISABIAL, Miguel Hernández University, Alicante, Spain.
Surg Oncol. 2024 Dec;57:102129. doi: 10.1016/j.suronc.2024.102129. Epub 2024 Sep 5.
Breast cancer (BC) is the most common malignant tumor in women. Between 20 % and 30 % of patients develop metastases from BC, 50 % of them in the liver. The mean survival rate reported in patients with liver metastases from BC (LMBC) ranges from 3 to 29 months. The role of surgery in LMBC is not clearly defined. The objective of the present study was to determine the long-term survival and disease-free survival of patients undergoing surgery for LMBC and to identify the patients who most likely benefit from surgery.
This retrospective multicenter cohort study included all consecutive patients undergoing LMBC surgery at the participating European centers from January 1, 2010, to December 31, 2015. The ClinicalTrials.gov ID is NCT04817813.
A hundred women (mean age 52.6 years) undergoing LMBC surgery were included. Five-year disease-free survival was 29 %, and 5-year overall survival was 60 %. Median survival after BC surgery was 12.4 years, and after LMBC surgery, 7 years. Patients with ECOG 1, ASA score I-II, metachronous LMBC, positive hormone receptors, and who had received neoadjuvant and adjuvant hormone treatment obtained the best overall and disease-free survival results.
In cases of correct patient selection and as part of a comprehensive onco-surgical strategy, surgery for LMBC improves overall long-term survival. In our series, certain factors were linked to better disease-free and overall survival; consideration of these factors could improve the selection of the best candidates for LMBC surgery.
NCT04817813.
乳腺癌（BC）是女性中最常见的恶性肿瘤。20%至30%的患者会发生乳腺癌转移，其中50%转移至肝脏。据报道，乳腺癌肝转移（LMBC）患者的平均生存率为3至29个月。手术在LMBC中的作用尚不明确。本研究的目的是确定接受LMBC手术患者的长期生存率和无病生存率，并确定最可能从手术中获益的患者。
这项回顾性多中心队列研究纳入了2010年1月1日至2015年12月31日期间在参与研究的欧洲中心接受LMBC手术的所有连续患者。ClinicalTrials.gov标识符为NCT04817813。
纳入了100名接受LMBC手术的女性（平均年龄52.6岁）。5年无病生存率为29%，5年总生存率为60%。乳腺癌手术后的中位生存期为12.4年，LMBC手术后为7年。美国东部肿瘤协作组（ECOG）评分为1、美国麻醉医师协会（ASA）评分I-II、异时性LMBC、激素受体阳性且接受过新辅助和辅助激素治疗的患者获得了最佳的总生存率和无病生存率结果。
在正确选择患者的情况下，作为综合肿瘤外科策略的一部分，LMBC手术可提高总体长期生存率。在我们的系列研究中，某些因素与更好的无病生存率和总生存率相关；考虑这些因素可改善LMBC手术最佳候选者的选择。
NCT04817813。
